<DOC>
	<DOCNO>NCT00647140</DOCNO>
	<brief_summary>Medullary thyroid carcinoma ( MTC ) rare tumor arise C cell thyroid gland belong endocrine tumor . 18F-DOPA PET , base tha capacity endocrine tumor cell take-up , decarboxylate store amino-acids , 3-4-dihydroxyphenylalanine ( DOPA ) , use image endocrine tumor . The aim study evaluate contribution 18F-DOPA whole-body PET detection recurrence patient proven recurrent MTC without evidence recurrence metastasis several image modality .</brief_summary>
	<brief_title>Clinical Evaluation 18F-DOPA Positron Emission Tomography Medullary Thyroid Cancer</brief_title>
	<detailed_description>In patient MTC persistently elevate calcitonin level , challenge find site residual disease . Since satisfy treatment surgery , early detection precise location important . Tumor localization technique usually perform , include ultrasonography neck liver , chest abdomen , bone scintigraphy , isotopic scan even PET FDG poorly sensitive . The use 18F-DOPA may sensitive specific engineering localization metastatic disease . The study include 100 patient persistent MTC demonstrate elevated tumor marker ( calcitonin CEA ) evidence recurrence morphological imaging procedure . 18F-DOPA whole-body PET perform 30 minute IV injection 4 MBq/kg 18F-DOPA , patient fast 6 hour prior start examination . All 18F-DOPA PET evaluate independently two experience nuclear medicine physician tracer accumulation exceed normal uptake tissue rat pathologic finding . The sensibility efficiency 18F-DOPA PET analyse Malignant tissue confirm histology surgery biopsy follow-up one year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Carcinoma , Medullary</mesh_term>
	<mesh_term>Dihydroxyphenylalanine</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Inclusion criterion : Patients 18 year old medullary thyroid cancer / carcinoma Patients medullary thyroid cancer / carcinoma recurrence , high calcitonin level / rate , 100pg/ml , associate high CEA ( Carcinoembryonic Antibodies ) level / rate , date less 3 month Patients less 3 month conventional image checkup ( cervical ultrasonography , cervicalchestabdomen tomography / magnetic resonance imaging , abdomen ultrasonography , osseous / bone radionuclide image ) , tumor site certainty locate Informed Consent Form sign dated patient Patients `` SECURITE SOCIALE '' affiliate Exclusion criterion : Pregnant suckle woman Women able procreate , without efficient birth control Patients already include another Nuclear Medicine Imaging research protocol use ionizing radiation ; efficient dose accumulation exceed 20 mSv .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Thyroid neoplasm</keyword>
	<keyword>Thyroid carcinoma</keyword>
	<keyword>Medullary carcinoma</keyword>
	<keyword>Positron Emission Tomography ( PET )</keyword>
	<keyword>18F-L DOPA</keyword>
	<keyword>Calcitonin</keyword>
	<keyword>Carcinoembryonic Antibodies</keyword>
	<keyword>Cervical ultrasonography</keyword>
	<keyword>Cervical-chest-abdomen tomography</keyword>
	<keyword>Cervical-chest-abdomen magnetic resonance imaging</keyword>
	<keyword>Osseous radionuclide imaging</keyword>
	<keyword>Post-PET surgery</keyword>
	<keyword>Post-PET biopsy</keyword>
	<keyword>Post-PET histology</keyword>
</DOC>